ARS Pharmaceuticals (SPRY) Receivables - Net (2024 - 2026)

ARS Pharmaceuticals has disclosed Receivables - Net across 3 years of filings, most recently posting $28.7 million for Q1 2026.

• Receivables - Net for Q1 2026 came in at $28.7 million, up 208.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.7 million (up 208.09% YoY), and the FY2025 annual result was $25.3 million, up 210.06% from the prior year.
• Receivables - Net came in at $28.7 million for Q1 2026 at ARS Pharmaceuticals, up from $25.3 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $36.5 million in Q3 2025 to a low of $773000.0 in Q3 2024.
• The 3-year median for Receivables - Net is $25.1 million (2025), against an average of $19.1 million.
• Across the five-year window, Receivables - Net jumped 4615.52% in 2025 and surged 208.09% in 2026, its largest moves.
• ARS Pharmaceuticals' Receivables - Net stood at $8.2 million in 2024, then surged by 210.06% to $25.3 million in 2025, then rose by 13.08% to $28.7 million in 2026.
• The last three Receivables - Net figures came in at $28.7 million (Q1 2026), $25.3 million (Q4 2025), and $36.5 million (Q3 2025), per Business Quant data.